Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesGlobeNewsWire • Thursday
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/11/24
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaGlobeNewsWire • 03/07/24
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceGlobeNewsWire • 01/11/24
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/11/23
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/14/23
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/02/23
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 10/30/23
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 10/26/23
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaGlobeNewsWire • 10/26/23
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell TherapyGlobeNewsWire • 08/16/23
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/14/23
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) BiosciencesGlobeNewsWire • 07/31/23
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T TherapyGlobeNewsWire • 06/15/23
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a BetZacks Investment Research • 06/12/23
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T TherapyGlobeNewsWire • 06/12/23
Wall Street Analysts Believe Mustang Bio, Inc. (MBIO) Could Rally 711.55%: Here's is How to TradeZacks Investment Research • 05/26/23
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio UpdatesGlobeNewsWire • 05/18/23
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/23
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell TherapyGlobeNewsWire • 05/11/23